Introduction
Persistent infection with a high risk HPV type is the main cause for cervical cancer. The implementation of screening programs, notably Pap testing, followed by management of detected pre-cancerous cervical lesions, has reduced cervical cancer incidence and mortality in most developed countries by more than half [1, 2] . Certain vulnerable populations, including Canadian Indigenous women, experience a disproportionate burden of cervical cancer morbidity and mortality. This is likely a consequence of non-participation in screening or follow-up care [3, 4] , both of which are linked to social determinants of health and a legacy of colonization differentially impacting health outcomes and health resources for Indigenous populations in Canada [5] . Increased prevalence of risk factors in these communities, including persistent infection by oncogenic types of HPV and high rates of cigarette smoking, are associated with the increased risk for cervical cancer [2] [3] [4] 6] . Indeed, Indigenous groups in Canada, namely First Nations, Metis and Inuit communities, have a 2-to 20-fold higher incidence of cervical cancer than non-Indigenous women [3, 4, 6, 7] . Because of the effects of experiences of social exclusion, and histories of reinforced deviations from their cultures on health behaviours, existing cervical screening programs may not adequately reach women from Indigenous populations [4, 6, 8, 9] . Additionally, women living in Northern Ontario likely experience other barriers with accessing cervical screening and related interventions, including discontinuity of care, and geographic and transportation barriers [9] . In fact, cervical screening participation rates are lowest in this region of Ontario [10] .
The ACCSS (www.accssfn.com) is a mixed-methods research project consisting of both qualitative and quantitative components. The qualitative portion of the study [11] [12] [13] [14] was structured to complement and inform the quantitative portion [15] . The qualitative studies included interviews with community health care providers (HCPs) and focus groups with community women who did not have formal health education, while the quantitative part was a two-arm, cluster-randomized controlled trial. We were interested in how many female community members consented to participate in the trial and in cervical screening. The primary aim of this trial was based on the hypothesis that an offer of self-collected HPV testing will increase uptake of cervical cancer screening in First Nations communities compared to an offer of the provincial standard of HCP-administered Pap cytology testing.
Methods: Participants, interventions, and outcomes
Study setting. The Anishinaabek Cervical Cancer Screening Study (ACCSS) began in 2009 as a successful pilot study in the largest of the First Nations Robinson Superior Treaty communities in the Thunder Bay district, conducted by the principal investigator (Ingeborg Zehbe), cancer biologist, in collaboration with another current ACCSS team member (Alberto Severini), virologist, and a medical anthropologist (Helle Moeller) [16] . The First Nations partner communities each have between ~ 70 and 800 band members and are scattered around the shores of Lake Superior and Lake Nipigon in Northwest Ontario, Canada [15, 16] .
In 2011, the ACCSS continued as a larger study with interdisciplinary expertise in cancer biology, virology, public health, epidemiology, medical anthropology and women's health sociology [15] . Within a participatory action research (PAR) framework, the ACCSS places considerable emphasis on collaborative discussion with the partner communities and the ethical space concept [11] , a term coined by philosopher Roger Poole and adapted for Indigenous research ethics by Indigenous scholar Willie Ermine [17, 18] . Ethical space is a widely accepted tool used by the Canadian research community dealing with Indigenous research. This concept was recently elaborated upon during the "Work Better Together" conference in Vancouver, British Columbia in February 2015 with Indigenous delegates [scholars and Elders] who have been instrumental for developing and updating chapter 9 of the Canadian Tri-Council Statement Policy on Research with Humans [19] .
To comply with the concept of PAR, we used the lay health worker approach for implementation of the trial, e.g. for enrolling participants. In each participating First Nations community, one community-based research assistant (CBRA) was hired by the Research Team. CBRAs were recruited preferably from band members. The health directors in each community helped with the recruitment. The minimum education of applicants was set to high-school diploma. During a two-day workshop, the CBRAs were trained in clinical aspects of HPV and cervical cancer and how to recruit trial participants. In addition a community steering committee (CSC) was formed with one community member from each community (usually the health director or CHR). We also implemented the idea of a publication steering committee (PSC) formed by interested community members for publications regarding the ACCSS (see dissemination).
Eligibility criteria. During an All Chiefs' meeting in Thunder Bay (November 2010) representing the Robinson Superior Treaty communities, to which IZ was invited, the then attending chiefs decided to participate in the proposed larger cervical screening study. Henceforth, any of these communities was eligible to join the study (community-level eligibility) whereupon research agreements were ratified individually with each participating community between December 2010 and June 2011.
In Canada, "reserve" refers to a plot of land set aside for First Nations people after contact with the Canadian government. Only individuals who are registered with these communities (band members) have rights to this land. As a result, women can live with band members on-reserve but may not self-identify as First Nations. Women registered with any of the partner First Nations communities, who were between 25 and 69 years old and who lived on-reserve or Crown land acquired through communication with Aboriginal Affairs and Northern Development Canada (AANDC) [20] were eligible to participate (individual-level eligibility). An estimated number of 1002 eligible women (Table 1) was obtained through community counts directly extracted on July 15, 2014 from the AANDC Indian Registration System which, as of July 15, 2014, was last updated on December 31, 2013. The registration numbers did not account for late reporting of births or deaths, and only reflect residency codes for individuals affiliated with the particular First Nations. We considered all eligible women from the participating communities as the denominator for determining cervical cancer screening uptake.
Interventions. We divided the communities into the two study arms. In phase 1, each community received either a first offer of self-collection of a vaginal swab for HPV DNA testing (arm A), or a first offer of Pap testing (arm B), the standard screening method in Ontario. In phase 2, we then invited the women who did not accept the first screening modality to participate in the alternative one.
HPV self-sampling and Pap testing: Self-sampling kits consisted of a sterile, plain polyester Dacron swab and transportation tube (Copan Diagnostics Sterile Plain Swab; licensed in Canada by Inverness Medical: #552C), a postage-paid envelope and an instructional pamphlet for collecting a vaginal sample. CBRAs or participants mailed the Dacron swabs at ambient temperature to the British Columbia Centre for Disease Control (BCCDC) where they were tested for 14 high-risk HPV infections as a group, using the Health Canada-approved Roche Cobas 4800 HPV test [21] [22] [23] . DNA extraction was performed and specimen integrity monitored, as described previously [16] . The Cobas test was employed because HPV tests based on partial or full genotyping using PCR methods have been approved by Health Canada. PCR-based HPV tests generally have similar sensitivity between self-collected and clinician-taken samples [24] . Cobas types HPV 16 and 18 and detects 12 additional high-risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) .
In Ontario, Pap cytology is covered under the provincial health care insurance plan. Screening is opportunistic. Existing Ontario cervical screening guidelines [25] recommend that women between the ages of 21 and 70, ever having been sexually active, attend screening every three years if three previous screening tests indicate negative results. Abnormal Pap cytology results are checked after 6 months and if they persist there is a referral to a colposcopist. CBRAs scheduled Pap test appointments for ACCSS trial participants in the control group ad hoc, through Well-Women clinics if such were organized in the partner communities or with participants' health care providers outside the communities. They invited residents to participate in the screening offered throughout the study, even if they had attended a Pap test within the recommended timeframe, as our research component was outside of "standard care". CBRAs and the team also encouraged eligible women to continue following their personal HCPs recommendations for any concurrent cervical screening or follow-up. The sample collection methodology, interpretation of results, and follow-up communication with the participants followed the current Ontario Cervical Screening protocol for primary care practitioners [26] .
Outcomes. The primary outcome measure was the uptake of cervical screening based on a first offer of HPV self-collected sample compared to the uptake based on a first offer of Pap testing. The second primary outcome measure was the cumulative uptake for both screening modalities. Women were recruited into the trial by lay health worker/community liaison CBRAs. The third primary outcome measure was psychosocial status related to cervical screening. This included participants' feelings toward their bodies, their general health and their social support after hearing cervical screening results. Psychosocial indicators were measured using a seven-point Likert scale at three and six months after baseline in follow-up questionnaires to assess temporal changes in cervical screening experiences. A psychosocial score was generated for each participant relative to the number of questions they answered. Sub-scores were calculated for questions related to worry as well as for questions related to satisfaction of support and information received.
Participant time line.
Communities enrolled and subsequently participated in the qualitative portion of the study between 2011 and 2012 [8, 9, [11] [12] [13] [14] . The randomization and allocation of the quantitative portion of ACCSS (i.e. the screening trial) occurred in February 2013. Enrolment in the first phase of the trial was staggered between communities, with the trial launching between May and November 2013. We scheduled the first offer of cervical screening for 3 months in each community. A subsequent intervention break of 1-2 months separated the first offer of screening from the second offer of screening, to allow communities and researchers an opportunity to reflect on the progress. The second offer of screening also lasted for 3 months. Participant recruitment was completed in August 2014. Sample size. Trial sample size calculation was based on the difference in screening uptake between the two trial arms after the first screening method is offered. It was estimated that current screening uptake in First Nations in Northwest Ontario is ~22.5%, which is half the general population rate of 45%. This estimate was based on: i) previous research of annual Pap test screening in the general population in Northwest Ontario [27] , ii) an allowance for the over-representation of First Nations women in cervical cancer diagnoses by at least a factor of 2 [28] and possibly more [29, 30] and iii) knowing that a large proportion of cervical cancer diagnoses are among the never or underscreened [31] . Sample size calculations were done for each of three scenarios where the selfsampling rate is assumed to increase the Pap screening participation by ~45%. This assumption was based on previous Swedish studies that between 32% and 58% (mean 45%) of women with no Pap test during the last six years accepted self-sampling [33] [34] . We estimated three scenarios: (1) no change (baseline of 22.5%) in screening uptake in the arm initially offered Pap testing, uptake 45% higher in the other arm, i.e. 32.5%; (2) uptake in the arm initially offered Pap testing 30%, and 43.5% in the other arm; and (3) uptake in the arm initially offered Pap testing 45%, and 65.3% in the other arm. A priori, we estimated that a total of ~ 1000 women would be potentially eligible to be offered screening. If clustering were disregarded in the power calculations, then, with ~ 500 subjects per arm, at 5% alpha level, the trial would have a power of >96% to detect a difference in uptake for all three scenarios. Clustering, while improving the practical aspects of conducting this trial, reduces its statistical power. The extent of the reduction depends on the magnitude of the intra-cluster correlation (ICC). The ICC itself is based on the variance "between" and "within" clusters [35] . With all other parameters in the sample size estimation set as above, and setting the power to 80%, we calculated the maximum level of ICC permissible to be 0.0063 under scenario 1, 0.0158 under scenario 2, and 0.0461 under scenario 3. While the true ICC for study outcome cannot be known in advance, in light of other studies [36] [37] [38] and size of our clusters [39] it is likely to be less than the maximum allowable in the sample size calculation, especially for the latter two scenarios.
Recruitment. Through previous meet and greet dialogues in 2011 [11] and an educational workshop in 2012 [13] with community stakeholders (health directors, HCPs and political leadership), we established recruitment strategies to enrol participants into the screening trial.
[ Table A ]. All CBRAs invited women to participate at educational events hosted in their communities and distributed pamphlets. The majority also used personal communication to recruit eligible women into the study, including door-to-door visits and personal appointments at health centres. At these events, potential participants were told about cervical cancer screening as well as what type of screening was offered in their community as part of the screening trial. During the educational session and within the pamphlet developed for the communities [40] , participants were able to see which communities were participating in the project. However, the team did not reveal which specific screening modality was being offered in each community. As a result, participants could potentially use their social ties to help recruit more women from other partner communities into the trial, and this could be done without differential bias. Eligible women were not informed upon enrolment that a second round of screening with the alternate method would subsequently be offered, to prevent biasing their choice to participate in the initially offered screening method.
Methods: Assignment of interventions (for controlled trials)
Allocation. Compliance with the trial's randomization allocation was monitored by measuring cervical screening participation, by examining the submitted HPV samples and by noting the date recorded on the participant's most recent cytology report in CytoBase (the Ontario data bank for Pap-screened women) [41] .
We stratified communities according to size (small, medium, and large) and randomly assigned them to the first offer intervention type within their strata. Using band registration numbers from January 2013 [15] , we defined a small community as less than or equal to 360 total registered females, a medium community as between 361 and 910 total registered females and a large community as more than 910 total registered females. There were seven medium communities, three small communities, and one large community. By conducting a stratified randomization, we intended for approximately equivalent numbers of women to be offered screening in each arm. We randomized communities instead of individuals, to build upon the community engagement element of the project as well as to reduce contamination between the control group (those who were first offered Pap testing) and the intervention group (those who were first offered the HPV self-test). A research assistant external to the Research Team performed the randomization. First, we randomly assigned the seven medium sized communities. To do so, each community was assigned a random number and then those with the four highest numbers were placed into one arm and the remaining three into the other arm. We then applied the same approach to the three smaller communities. Lastly, we placed the one large community in the arm with only three medium sized communities in it.
Masking. Blinding to the allocated screening arm was not possible in the ACCSS trial, as participating women were aware of the cervical screening option they were offered. Nevertheless, the Research Team used several approaches to mitigate potential biases that may be introduced by the lack of blinding. First, the screening allocation for each community was not revealed until it was time to conduct launch events for their communities. The research coordinator called the respective CBRAs to implement the randomization allocation, and also communicated with the community health director and the leadership. Second, inasmuch as possible, the Research Team strived to keep the intervention allocation contained to each community to prevent intercommunity contamination and dilution of intervention effect. Thus, the intervention allocation of specific communities were not made known to other communities within the study.
Methods: Data collection, management, and analysis
Data collection methods. CBRAs were trained to administer the questionnaires according to protocol during their initial training with the study. They first went through the informed consent form with each potential participant. The informed consent form included background information on the study, procedures involved in the research, potential benefits and potential harms/discomforts, incentives, confidentiality, access to research information, withdrawal information, and information about participation. All participants who consented to participate in the trial were then invited to complete the baseline questionnaire [Appendix] through a structured interview with their CBRA. The baseline questionnaire incorporated material from other HPV and cervical screening studies, including TOMBOLA [42] , HITCH [43] and the ACCSS pilot study [16] and contained questions formulated to gain a better understanding of each participant's personal health, social and demographic information, and food security status as well as their feelings toward women's health care, psychosocial health, HPV and cervical cancer. We also asked how the participants would like to be contacted in the event of a positive or abnormal result. These details were necessary to appropriately follow-up the participants with results. A final section captured whether the participant would be willing to be contacted for follow-up questionnaires. These participants were then invited to complete follow-up questionnaires [Appendix] at the end of phases 1 and 2 to gather information about their general experience in cervical cancer screening, their willingness to do HPV self-sampling and their psychosocial health associated with cervical screening.
After the first offer of cervical screening was complete, the CBRAs reflected on the first phase of the trial with the Research Team as part of the PAR framework. This provided insight about the progress of PAR in the communities and helped CBRAs tailor their recruitment strategies for phase 2 based on what they found successful in phase 1. We expected retention in the trial for follow-up to be enhanced because of the CBRAs presence and social ties within their communities. As an incentive to participate, every tenth participant could win a grocery gift certificate worth CAD $100.
Data management. We linked the questionnaire and corresponding informed consent form by a unique random-identifier (five digit random number and five character random string), which became participants' unique study identification numbers. We created separate study databases in Microsoft Excel with built-in logic checks for range values, the interview schedule, administrative data and clinical outcome data. Trained research assistants manually entered questionnaire and administrative data under the supervision of the research coordinator (Brianne Wood), who also gathered and entered the clinical outcome data. Principal investigator (Ingeborg Zehbe) used a 30% random sample from the entire dataset to verify the data entry. A 5% discrepancy rate was used as a general indicator of appropriate data entry. Discrepancies >5% occurred within two conditional variables (Health question 6 and Food Security question 9), due to misunderstanding of the question by the participants. As a result, these questions were re-checked and re-entered by an external researcher, and any discrepancies identified at that stage (<3%) were corrected. The key that links personal contact information with subject identification number is stored in a secure location that is separate from the data storage location. Only the research coordinator and principal investigator have access to this key, and they de-identified the complete data collection as well as questionnaire responses. Other team members have access to de-identified data only. The analysis was performed on a data set that was frozen on June 14, 2015.
Permission was obtained (through the informed consent form) to access relevant screening participation information in CytoBase [41] for women who participated in the study. We linked the HPV self-sample tests to the participant Study ID, ensuring they were sent de-identified to the genotyping lab so that HPV test results could not be associated with any personal identifying information. The CBRAs did not have access to any test results. To communicate HPV test results back to the participants, the research team acted as an intermediary between the HPV testing centre and the participants' HCPs. We used a similar "results communication" method for the Pap tests by involving HCPs. We asked participants on the consent form if they would like to be contacted by a local or their own HCP in the event of a positive result. We approached collaborating HCPs and they accepted this "responsibility" to help out local participants who may not have a personal HCP or who preferred an alternative HCP.
Statistical methods. Screening uptake was determined by both intention-to-treat (ITT) and per protocol (PP) analyses, in recognition of limitations with both approaches [44] [45] [46] [47] [48] . Thus, in the ITT analysis, women from a community that terminated its participation in the trial were included in the analysis as having no screening uptake. Women who did not answer the questionnaire were assumed not to have accepted the offer of screening. However, women who received a screening test that was not of the type offered were included as if they had accepted the offer of the test that had been assigned to their community. In the PP analysis, women from a community that terminated its participation in the trial were excluded from analysis. Women who did not answer the questionnaire were assumed not to have accepted the offer of screening and analysis was based on the type of test that the women had actually undergone. For cluster-level analysis, we compared the proportion of cervical cancer screening uptake between screening modalities using a permutation test [49] . Percentage point (or "risk") difference with a 95% confidence interval (CI) was reported as calculated by the bootstrap method [50] . To account for differences in questionnaire response, a proxy for CBRA outreach and community participation, additional analysis of the clustered screening uptake data was completed by normalizing it to the number of women who completed baseline questionnaires in each community.
The assessment of psychosocial status used a nine-item instrument with domains of worries/concerns about cancer, self-efficacy and external factors such as the community and relationships, based on similarly published instruments [51, 52] . Each item was a seven-point Likert-type item. Psychosocial scores were obtained by calculating a mean score of all completed items for each respondent (after reverse-coding items 2, 4, and 8). We compared PP communityaveraged baseline scores obtained at the time of intervention rollout in each community between the arms, irrespective of whether the women had accepted the offer of a screening test. We intended that this would reflect the response to the educational and engagement component of the intervention at the community level. We computed means and 95% confidence intervals (as described above), and tested for difference between the arms by a permutation test. In a descriptive analysis, we computed the scores at follow-up time points 1 and 2 between the arms, regardless of community, to assess psychosocial scores before and after screening. We also compared scores between screened and not screened women.
We applied standard descriptive statistics to the non-clustered data, socio-demographic characteristics, health status and health service use as well as comfort with either screening modality. We compared this information between the arms using the Chi-square test, N-1 Chisquare test for 2×2 tables with any low (<5) expected counts [53] , the linear-by-linear association test for ordinal data [54] , the Mantel-Haenszel Chi-square test for stratified data, or the Welch's ttest for comfort scores. All statistical analyses were conducted using R version 3.1.0 [55] except for the linear-by-linear association test for which SPSS version 22 for Windows was used [56] . The alpha level was 0.05.
Methods: Monitoring
Following the nature of PAR, a communication network has been established between the research team and communities, through CBRAs, through a community steering committee of health managers and directors, and through the community leadership (e.g. Chief, and Council members). There was no need to have a traditional data monitoring committee to examine patient safety within the trial, as the cervical screening interventions pose little risk to individuals and communities in this pragmatic trial. Additionally, we did not expect dramatic differences in health outcomes between screening arms. Follow-up of abnormal Pap results follow the Ontario standard-of-care and high-risk HPV positivity would lead to follow-up with Pap initiated by the HCP of choice, as indicated on the informed consent form. Progress reports continue to be communicated to the communities through these established connections.
Ethics and dissemination
Ethics. The ACCSS trial was conducted in accordance with the Canadian Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans [19] and obtained ethics approval through the Lakehead University Research Ethics Board (#126 12-13/ROMEO #1463139). The Lakehead University Research Ethics Board and the Thunder Bay Regional Health Sciences Centre Research Ethics Board jointly approved the qualitative element of this project. Participation in cervical cancer screening as part of the ACCSS was voluntary. As such, all women who agreed to participate in the questionnaire or questionnaire and screening provided written informed consent. By the PAR nature of the project and the First Nations Research Ethics Principles of Ownership, Control, Access, and Possession (OCAP™), all data are jointly owned by the communities and Research Team. These OCAP™ principles also guide the research process and collaboration with community representatives and leadership [57] , and was ratified as part of the research agreements signed prior to start of the ACCSS. The trial registration number is International Standard Randomised Controlled Trial Number Register: ISRCTN84617261. There was minimal risk associated with participation in this study. Due to the nature of this intervention, the Research Team did not expect any serious physical adverse events to occur from the group allocation. Some participants could experience psychological discomfort because of the sensitive nature of cervical cancer. Consistent monitoring of the study sites and phone interviews with the health managers and the CBRAs ensured any major event be reported to study investigators. The Lakehead University Research Ethics Board was to be immediately notified if there were any serious incidents in any of the participating communities relevant to the study or study proceedings. Because of the low-risk nature of the trial, there were no explicit stopping guidelines. However, women and communities were reminded that they may withdraw at any point from the project without giving reason to the Research Team.
Dissemination. Knowledge translation includes community/regional, academic, and policy focuses, respectively. For academic dissemination of manuscripts in peer-reviewed journals, two individuals for each manuscript are recruited amongst CBRAs and HCPs to form an ad hoc PSC for feedback and input. Both PSC members are offered authorship if their feedback has been substantial. Manuscripts are then sent to the community health directors and political leadership for a one month comment period, giving them an opportunity to provide feedback. Abstracts for scientific meetings and conferences, notes in special-interest newsletters or magazines, articles and features are also submitted to the communities for input and feedback prior to publication. Strategic collaborations with key stakeholders such as the Society of Obstetricians and Gynaecologists of Canada, the Assembly of First Nations and Cancer Care Ontario ensure a fast translation of our results into First Nations Health policy, programs, and practice, so that findings from this study can be translated to other First Nations communities.
Appendices
Informed consent materials. A model consent form, baseline and follow-up questionnaires are attached to this protocol.
